Terms: = Brain cancer AND MAP2K1, MAPKK1, 5604, ENSG00000169032, Q02750, MEK1, MKK1, PRKMK1 AND Treatment
34 results:
1. KRAS is a molecular determinant of platinum responsiveness in glioblastoma.
Zuchegna C; Leone S; Romano A; Porcellini A; Messina S
BMC Cancer; 2024 Jan; 24(1):77. PubMed ID: 38225605
[TBL] [Abstract] [Full Text] [Related]
2. Rhizochalinin Exhibits Anticancer Activity and Synergizes with EGFR Inhibitors in Glioblastoma In Vitro Models.
Dyshlovoy SA; Hauschild J; Venz S; Krisp C; Kolbe K; Zapf S; Heinemann S; Fita KD; Shubina LK; Makarieva TN; Guzii AG; Rohlfing T; Kaune M; Busenbender T; Mair T; Moritz M; Poverennaya EV; Schlüter H; Serdyuk V; Stonik VA; Dierlamm J; Bokemeyer C; Mohme M; Westphal M; Lamszus K; von Amsberg G; Maire CL
Mol Pharm; 2023 Oct; 20(10):4994-5005. PubMed ID: 37733943
[TBL] [Abstract] [Full Text] [Related]
3. Dabrafenib, alone or in combination with trametinib, in BRAF V600-mutated pediatric Langerhans cell histiocytosis.
Whitlock JA; Geoerger B; Dunkel IJ; Roughton M; Choi J; Osterloh L; Russo M; Hargrave D
Blood Adv; 2023 Aug; 7(15):3806-3815. PubMed ID: 36884302
[TBL] [Abstract] [Full Text] [Related]
4. DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition.
Izquierdo E; Carvalho DM; Mackay A; Temelso S; Boult JKR; Pericoli G; Fernandez E; Das M; Molinari V; Grabovska Y; Rogers RF; Ajmone-Cat MA; Proszek PZ; Stubbs M; Depani S; O'Hare P; Yu L; Roumelioti G; Choudhary JS; Clarke M; Fairchild AR; Jacques TS; Grundy RG; Howell L; Picton S; Adamski J; Wilson S; Gray JC; Zebian B; Marshall LV; Carceller F; Grill J; Vinci M; Robinson SP; Hubank M; Hargrave D; Jones C
Cancer Discov; 2022 Mar; 12(3):712-729. PubMed ID: 34737188
[TBL] [Abstract] [Full Text] [Related]
5. Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAF
Schreck KC; Morin A; Zhao G; Allen AN; Flannery P; Glantz M; Green AL; Jones C; Jones KL; Kilburn LB; Nazemi KJ; Samuel D; Sanford B; Solomon DA; Wang J; Pratilas CA; Nicolaides T; Mulcahy Levy JM
Clin Cancer Res; 2021 Nov; 27(22):6197-6208. PubMed ID: 34433654
[TBL] [Abstract] [Full Text] [Related]
6. miR-424 induces apoptosis in glioblastoma cells and targets AKT1 and RAF1 oncogenes from the ERBB signaling pathway.
Gheidari F; Arefian E; Adegani FJ; Kalhori MR; Seyedjafari E; Kabiri M; Teimoori-Toolabi L; Soleimani M
Eur J Pharmacol; 2021 Sep; 906():174273. PubMed ID: 34153339
[TBL] [Abstract] [Full Text] [Related]
7. EIF4A3-induced circular RNA ASAP1 promotes tumorigenesis and temozolomide resistance of glioblastoma via NRAS/mek1/ERK1-2 signaling.
Wei Y; Lu C; Zhou P; Zhao L; Lyu X; Yin J; Shi Z; You Y
Neuro Oncol; 2021 Apr; 23(4):611-624. PubMed ID: 32926734
[TBL] [Abstract] [Full Text] [Related]
8. Hypoxia-induced acetylation of PAK1 enhances autophagy and promotes brain tumorigenesis via phosphorylating ATG5.
Feng X; Zhang H; Meng L; Song H; Zhou Q; Qu C; Zhao P; Li Q; Zou C; Liu X; Zhang Z
Autophagy; 2021 Mar; 17(3):723-742. PubMed ID: 32186433
[TBL] [Abstract] [Full Text] [Related]
9. Mutant ACVR1 Arrests Glial Cell Differentiation to Drive Tumorigenesis in Pediatric Gliomas.
Fortin J; Tian R; Zarrabi I; Hill G; Williams E; Sanchez-Duffhues G; Thorikay M; Ramachandran P; Siddaway R; Wong JF; Wu A; Apuzzo LN; Haight J; You-Ten A; Snow BE; Wakeham A; Goldhamer DJ; Schramek D; Bullock AN; Dijke PT; Hawkins C; Mak TW
Cancer Cell; 2020 Mar; 37(3):308-323.e12. PubMed ID: 32142668
[TBL] [Abstract] [Full Text] [Related]
10. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.
Fangusaro J; Onar-Thomas A; Young Poussaint T; Wu S; Ligon AH; Lindeman N; Banerjee A; Packer RJ; Kilburn LB; Goldman S; Pollack IF; Qaddoumi I; Jakacki RI; Fisher PG; Dhall G; Baxter P; Kreissman SG; Stewart CF; Jones DTW; Pfister SM; Vezina G; Stern JS; Panigrahy A; Patay Z; Tamrazi B; Jones JY; Haque SS; Enterline DS; Cha S; Fisher MJ; Doyle LA; Smith M; Dunkel IJ; Fouladi M
Lancet Oncol; 2019 Jul; 20(7):1011-1022. PubMed ID: 31151904
[TBL] [Abstract] [Full Text] [Related]
11. E6201, an intravenous mek1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases.
Babiker HM; Byron SA; Hendricks WPD; Elmquist WF; Gampa G; Vondrak J; Aldrich J; Cuyugan L; Adkins J; De Luca V; Tibes R; Borad MJ; Marceau K; Myers TJ; Paradiso LJ; Liang WS; Korn RL; Cridebring D; Von Hoff DD; Carpten JD; Craig DW; Trent JM; Gordon MS
Invest New Drugs; 2019 Aug; 37(4):636-645. PubMed ID: 30264293
[TBL] [Abstract] [Full Text] [Related]
12. Upregulation of EphB3 in gastric cancer with acquired resistance to a FGFR inhibitor.
Lee SY; Na YJ; Jeong YA; Kim JL; Oh SC; Lee DH
Int J Biochem Cell Biol; 2018 Sep; 102():128-137. PubMed ID: 30044964
[TBL] [Abstract] [Full Text] [Related]
13. Combined kinase inhibitors of mek1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.
Van Swearingen AED; Sambade MJ; Siegel MB; Sud S; McNeill RS; Bevill SM; Chen X; Bash RE; Mounsey L; Golitz BT; Santos C; Deal A; Parker JS; Rashid N; Miller CR; Johnson GL; Anders CK
Neuro Oncol; 2017 Oct; 19(11):1481-1493. PubMed ID: 28486691
[TBL] [Abstract] [Full Text] [Related]
14. Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy.
Kline CN; Joseph NM; Grenert JP; van Ziffle J; Talevich E; Onodera C; Aboian M; Cha S; Raleigh DR; Braunstein S; Torkildson J; Samuel D; Bloomer M; Campomanes AGA; Banerjee A; Butowski N; Raffel C; Tihan T; Bollen AW; Phillips JJ; Korn WM; Yeh I; Bastian BC; Gupta N; Mueller S; Perry A; Nicolaides T; Solomon DA
Neuro Oncol; 2017 May; 19(5):699-709. PubMed ID: 28453743
[TBL] [Abstract] [Full Text] [Related]
15. A new NFIA:RAF1 fusion activating the MAPK pathway in pilocytic astrocytoma.
Yde CW; Sehested A; Mateu-Regué À; Østrup O; Scheie D; Nysom K; Nielsen FC; Rossing M
Cancer Genet; 2016 Oct; 209(10):440-444. PubMed ID: 27810072
[TBL] [Abstract] [Full Text] [Related]
16. BRAF Status in Personalizing treatment Approaches for Pediatric Gliomas.
Olow A; Mueller S; Yang X; Hashizume R; Meyerowitz J; Weiss W; Resnick AC; Waanders AJ; Stalpers LJ; Berger MS; Gupta N; James CD; Petritsch CK; Haas-Kogan DA
Clin Cancer Res; 2016 Nov; 22(21):5312-5321. PubMed ID: 27217440
[TBL] [Abstract] [Full Text] [Related]
17. EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E-Mutant NSCLC Cell Lines.
Kim SM; Kim H; Jang KW; Kim MH; Sohn J; Yun MR; Kang HN; Kang CW; Kim HR; Lim SM; Moon YW; Kim JH; Paik S; Cho BC
Mol Cancer Ther; 2016 Jul; 15(7):1627-36. PubMed ID: 27196768
[TBL] [Abstract] [Full Text] [Related]
18. ROS-dependent activation of autophagy is a critical mechanism for the induction of anti-glioma effect of sanguinarine.
Pallichankandy S; Rahman A; Thayyullathil F; Galadari S
Free Radic Biol Med; 2015 Dec; 89():708-20. PubMed ID: 26472194
[TBL] [Abstract] [Full Text] [Related]
19. ERK1/2 acts as a switch between necrotic and apoptotic cell death in ether phospholipid edelfosine-treated glioblastoma cells.
Melo-Lima S; Lopes MC; Mollinedo F
Pharmacol Res; 2015; 95-96():2-11. PubMed ID: 25749008
[TBL] [Abstract] [Full Text] [Related]
20. MiR-152 functions as a tumor suppressor in glioblastoma stem cells by targeting Krüppel-like factor 4.
Ma J; Yao Y; Wang P; Liu Y; Zhao L; Li Z; Li Z; Xue Y
Cancer Lett; 2014 Dec; 355(1):85-95. PubMed ID: 25218589
[TBL] [Abstract] [Full Text] [Related]
[Next]
